{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T14:58:12Z","timestamp":1792335492630,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.clinthera.2015.09.018","type":"journal-article","created":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T08:54:26Z","timestamp":1445936066000},"page":"2811-2822","source":"Crossref","is-referenced-by-count":17,"title":["Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies"],"prefix":"10.1016","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct01355354","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Paul","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Millson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Brealey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Elsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-3039","authenticated-orcid":false,"given":"Muhammad","family":"Baluom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Mant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.09.018_bib1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1592\/phco.27.12.1693","article-title":"Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis","volume":"27","author":"Reynolds","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2015.09.018_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0889-857X(21)00171-X","article-title":"What is the natural history of rheumatoid arthritis?","volume":"19","author":"Pincus","year":"1993","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.clinthera.2015.09.018_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/art.30114","article-title":"An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2015.09.018_bib4","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1002\/art.23992","article-title":"Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial","volume":"58","author":"Weinblatt","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2015.09.018_bib5","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2015.09.018_bib6","unstructured":"Rigel Pharmaceuticals I. Rigel to focus on ITP, DLE and dry eye strategy provides multiple paths to phase 3\/NDA in next 2-3 years. Last updated 2013. Rigel web site. http:\/\/ir.rigel.com\/phoenix.zhtml?c=120936&p=irol-newsArticle&id=1852213. Accessed November 11, 2014."},{"key":"10.1016\/j.clinthera.2015.09.018_bib7","unstructured":"Rigel Pharmaceuticals I. Fostamatinib \u2013 IgAN. Last updated 2014. Rigel web site. http:\/\/www.rigel.com\/rigel\/IgAN. Accessed November 11, 2014."},{"key":"10.1016\/j.clinthera.2015.09.018_bib8","unstructured":"Rigel Pharmaceuticals I. Fostamatinib (R788) \u2013 ITP. 2014. Last updated 2014. Rigel web site. http:\/\/www.rigel.com\/rigel\/ITP. Accessed November 11, 2014."},{"key":"10.1016\/j.clinthera.2015.09.018_bib9","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.23428","article-title":"An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus","volume":"58","author":"Bahjat","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2015.09.018_bib10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1517\/13543784.13.7.743","article-title":"Targeting Syk as a treatment for allergic and autoimmune disorders","volume":"13","author":"Wong","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2015.09.018_bib11","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1124\/dmd.110.032151","article-title":"Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation","volume":"38","author":"Sweeny","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2015.09.018_bib12","first-page":"366","article-title":"Relationship between high serum digoxin levels and toxicity","volume":"35","author":"Tuncok","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.09.018_bib13","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1001\/archinte.158.22.2444","article-title":"Digoxin toxicity: an evaluation in current clinical practice","volume":"158","author":"Williamson","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2015.09.018_bib14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00007691-199712000-00001","article-title":"Itraconazole decreases renal clearance of digoxin","volume":"19","author":"Jalava","year":"1997","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2015.09.018_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1067\/mcp.2000.107579","article-title":"Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein","volume":"68","author":"Westphal","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.09.018_bib16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/00003088-200746090-00005","article-title":"Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux","volume":"46","author":"Igel","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2015.09.018_bib17","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry. Drug interaction studies -- study design, data analysis, implications for dosing, and labeling recommendations. Draft guidance. Last updated 2012. US Food and Drug Administration Web site. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm292362.pdf. Accessed August 29, 2013."},{"key":"10.1016\/j.clinthera.2015.09.018_bib18","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions. Last updated Apr. 2010. European Medicines Agency Web site. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/05\/WC500090112.pdf. Accessed August 29, 2013."},{"key":"10.1016\/j.clinthera.2015.09.018_bib19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/00498250802017715","article-title":"A regulatory viewpoint on transporter-based drug interactions","volume":"38","author":"Zhang","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clinthera.2015.09.018_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/dmd.110.035881","article-title":"The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672","volume":"39","author":"Elsby","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2015.09.018_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/0091270011436344","article-title":"Review of P-gp inhibition data in recently approved new drug applications: utility of the proposed [I(1)]\/IC(50) and [I(2)]\/IC(50) criteria in the P-gp decision tree","volume":"53","author":"Agarwal","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2015.09.018_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/clpt.2008.195","article-title":"Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug","volume":"85","author":"Fenner","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.09.018_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bcp.12048","article-title":"Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies","volume":"76","author":"Baluom","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2015.09.018_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1365-2125.2003.01969.x","article-title":"The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a Phase I unit","volume":"57","author":"Purkins","year":"2004","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815011492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815011492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T13:20:25Z","timestamp":1653398425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815011492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0149291815011492"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.09.018","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}